Moderna’s AI-Built Cancer Vaccine Clears Phase 3 With Merck
来源：PYMNTS | 发布时间：2026-09-30
摘要：全球首个 III 期成功的个性化 mRNA 癌症疫苗，开启 AI + 肿瘤免疫治疗新阶段。 中：国际
Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be. That approach just cleared its biggest test.
Moderna and Merck announced Aug. 19 that their Phase 3 trial of intismeran autogene, a cancer therapy built individually for each patient, met its primary endpoint in melanoma patients whose tumors had been surgically removed. That makes it the first positive Phase 3 result recorded for this category of treatment, the companies said in a joint statement. “These Phase 3 findings represent a pivotal moment for the field of cancer research,” Moderna CEO Stéphane Bancel said.
What makes intismeran commercially distinct is that AI isn’t just speeding up research. It’s a direct input into the product itself. Each dose is built by sequencing a patient’s own tumor and identifying which mutations are worth targeting. Moderna has described using machine learning to analyze that data and predict which mutations are most likely to trigger a strong immune response, the computational approach reviewed in peer-reviewed research published in Biomarker Research. That prediction becomes part of the actual treatment a patient receives, not just an analysis that speeds up work in a lab.
Moderna 与默沙东 mRNA 肿瘤疫苗 III 期阳性，AI 深度参与靶点设计
近日，Moderna（莫德纳）与默沙东联合宣布，个性化mRNA癌症疫苗intismeran autogene（V940/mRNA-4157）联合帕博利珠单抗，用于高危黑色素瘤术后辅助治疗的III期INTerpath-001试验，顺利达成无复发生存期与无远处转移生存期双重终点。这是全球首个III期临床获得阳性结果的个体化mRNA肿瘤疫苗。受该消息刺激，Moderna当日股价收盘暴涨约177%，创下上市以来最大单日涨幅。
这款疫苗的研发过程中，AI扮演了关键角色。公开信息显示，Moderna和默沙东采用了一套集成的AI算法，从海量测序数据中筛选出最有可能被免疫系统识别的突变。如今AI已不再是停留在PPT中的研发辅助工具，而是切实进入了“患者数据→新抗原筛选→个体化药物设计→临床验证→患者获益”的完整研发链条。
就在Moderna消息公布次日，英矽智能宣布与专注于下一代RNA创新药研发的元码智药达成研发合作，双方将围绕AI新抗原预测与序列设计、环状mRNA、靶向递送、自动化实验及智能制造等领域，共建下一代mRNA AI原生研发引擎。mRNA肿瘤疫苗的热度，正将AI制药推到新的聚光灯下。
AI究竟是如何嵌入mRNA肿瘤疫苗研发流程的？英矽智能联合CEO兼首席科学官任峰在接受21世纪经济报道记者采访时指出，肿瘤疫苗领域非常适合AI技术介入：若采用mRNA技术开发肿瘤疫苗，单次最多可靶向二三十个癌症相关突变，但患者体内的突变数量可达数百上千个，而AI可结合已积累的公开数据与项目数据，辅助完成抗原筛选，从数百个突变中筛选出最能激活人体免疫的靶点；此外，AI还可用于优化递送系统，辅助肿瘤疫苗精准递送到病灶位置。
“mRNA肿瘤疫苗的III期成功，证明了肿瘤疫苗这一药物形式的可行性。”任峰表示。
但任峰同时指出，Moderna这款个性化肿瘤疫苗定价较高、可及性有限，商业价值或许不及科学价值，“未来还需要向通用型肿瘤疫苗方向探索”。